As clinical cohorts involving combination VEGF/TGFβ and immune checkpoint blockade treatment mature, determining which patients respond to this therapy, but also which patients are refractory and the mechanism that initiates tumor escape is of importance. The gene discussed is TGFB1; the disease is neoplasm.